Akebia Therapeutics shares are trading higher after Piper Sandler upgraded the stock from Neutral to Overweight and raised its price target from $2 to $4.
Portfolio Pulse from Benzinga Newsdesk
Akebia Therapeutics' stock has been upgraded from Neutral to Overweight by Piper Sandler, with the price target raised from $2 to $4.
May 31, 2023 | 7:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akebia Therapeutics (AKBA) receives an upgrade from Piper Sandler, raising its rating to Overweight and increasing the price target from $2 to $4.
The upgrade from Piper Sandler is a positive signal for Akebia Therapeutics, as it indicates increased confidence in the company's prospects. The raised price target from $2 to $4 suggests a potential upside for the stock, which may lead to short-term price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100